Pure Global AI
NCT06409026Not yet recruiting

Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Effect of Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
Mayo ClinicPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pulmonary Arterial Hypertension
Drug/Device/Intervention
Sotatercept
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mayo Clinic
Location
Rochester, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
May 01, 2024
End date
Feb 01, 2025
Enrollment
21 participants
Primary outcome

Pulmonary arterial mean pressure/Cardiac Output (PA/CO) at peak exercise

Summary

The purpose of this study is to see if the drug sotatercept given for 36 weeks improves the
 functioning of the heart and improves quality of life.

ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationStenosis of pulmonary arteryPulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06409026
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06409026 through Pure Global AI's free database. This Phase 4 trial is sponsored by Mayo Clinic and is currently Not yet recruiting. The study focuses on Pulmonary Arterial Hypertension. Target enrollment is 21 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.